These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27460820)

  • 21. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
    Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
    Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.
    Bagi CM; Christensen J; Cohen DP; Roberts WG; Wilkie D; Swanson T; Tuthill T; Andresen CJ
    Cancer Biol Ther; 2009 May; 8(9):856-65. PubMed ID: 19458500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
    Hokland SL; Horsman MR
    Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
    Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
    Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
    Schem C; Bauerschlag D; Bender S; Lorenzen AC; Loermann D; Hamann S; Rösel F; Kalthoff H; Glüer CC; Jonat W; Tiwari S
    BMC Cancer; 2013 Jan; 13():32. PubMed ID: 23347638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
    Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
    Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
    Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
    Siemann DW; Shi W
    Anticancer Res; 2008; 28(4B):2027-31. PubMed ID: 18751370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
    Zhang W; Shi X; Peng Y; Wu M; Zhang P; Xie R; Wu Y; Yan Q; Liu S; Wang J
    PLoS One; 2015; 10(6):e0129603. PubMed ID: 26057751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
    Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
    J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
    [No Abstract]   [Full Text] [Related]  

  • 37. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
    Ströbel P; Bargou R; Wolff A; Spitzer D; Manegold C; Dimitrakopoulou-Strauss A; Strauss L; Sauer C; Mayer F; Hohenberger P; Marx A
    Br J Cancer; 2010 Jul; 103(2):196-200. PubMed ID: 20571495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effect of vascular-leakage-blocker Sac-1004 and antiangiogenic drug sunitinib on tumor angiogenesis.
    Lee K; Agrawal V; Kim K; Kim J; Park H; Lee S; Kim YM; Suh YG; Kwon YG
    Biochem Biophys Res Commun; 2014 Aug; 450(4):1320-6. PubMed ID: 25003323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
    Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.